Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Acute Myeloid Leukemia
97%
Cytogenetically Normal Acute Myeloid Leukemia
21%
Leukemia Patients
16%
Leukemia
16%
Adult Patients
15%
Overall Survival
15%
Complete Remission
15%
De Novo Acute Myeloid Leukemia
14%
European LeukemiaNet
13%
Older Patients
10%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
10%
Nucleophosmin 1 (NPM1)
9%
Gene mutation
9%
Older Adults
8%
Black Men
8%
Clinical High Risk
8%
Point mutation
7%
Clinical Trials
7%
Risk Stratification
7%
Prognostic Impact
7%
Adult Acute Lymphoblastic Leukemia
6%
Chemotherapy
6%
Genetic Features
6%
Cytarabine
6%
Core Binding Factor Leukemia
6%
Myeloproliferative Neoplasms
6%
Favorable Outcome
6%
Isocitrate Dehydrogenase 1 (IDH1)
6%
Complex Karyotype
6%
Genetic Risk
6%
Hematologic Neoplasms
5%
3-point
5%
Lymphoblastic Leukemia
5%
NTRK2
5%
Overexpression
5%
FMS-like Tyrosine Kinase 3 (FLT3)
5%
Gene Signature
5%
Medicine and Dentistry
Acute Myeloid Leukemia
81%
Leukemia
21%
Diseases
16%
Malignant Neoplasm
13%
Overall Survival
12%
Clinical Trial
11%
De Novo Acute Myeloid Leukemia
10%
Gene Mutation
9%
NPM1
8%
Oncology
8%
Genetic Risk
7%
Hematopoietic Stem Cell Transplantation
7%
Risk Stratification
6%
High Risk Population
6%
Karyotype
6%
Neoplasm
6%
Sulfhemoglobinemia
6%
Point Mutation
5%
Lymphoid Leukemia
5%
Core Binding Factor
5%
Event Free Survival
5%
microRNA
5%
Gene Expression Profiling
5%
Biochemistry, Genetics and Molecular Biology
Myeloid
100%
Overall Survival
17%
Genetics
13%
Gene Mutation
11%
Genomics
11%
NPM1
10%
Stem Cell
9%
Clinical Trial
8%
MicroRNA
8%
Isoform
7%
Karyotype
7%
RNA Sequence
7%
Cytogenetics
7%
Genetic Risk
7%
Gene Expression
6%
Gene Expression Profiling
6%
High Risk Population
6%
Event Free Survival
5%
B Cell
5%